Tumor Suppressor Proteins
"Tumor Suppressor Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins that are normally involved in holding cellular growth in check. Deficiencies or abnormalities in these proteins may lead to unregulated cell growth and tumor development.
| Descriptor ID |
D025521
|
| MeSH Number(s) |
D12.776.624.776
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Tumor Suppressor Proteins".
Below are MeSH descriptors whose meaning is more specific than "Tumor Suppressor Proteins".
This graph shows the total number of publications written about "Tumor Suppressor Proteins" by people in this website by year, and whether "Tumor Suppressor Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 1 | 3 |
| 1996 | 1 | 3 | 4 |
| 1997 | 1 | 1 | 2 |
| 1998 | 2 | 0 | 2 |
| 1999 | 1 | 0 | 1 |
| 2000 | 4 | 0 | 4 |
| 2001 | 4 | 0 | 4 |
| 2002 | 2 | 2 | 4 |
| 2003 | 3 | 6 | 9 |
| 2004 | 4 | 6 | 10 |
| 2005 | 1 | 9 | 10 |
| 2006 | 1 | 1 | 2 |
| 2007 | 1 | 2 | 3 |
| 2008 | 5 | 1 | 6 |
| 2009 | 6 | 2 | 8 |
| 2010 | 3 | 1 | 4 |
| 2011 | 3 | 6 | 9 |
| 2012 | 2 | 2 | 4 |
| 2013 | 4 | 4 | 8 |
| 2014 | 3 | 2 | 5 |
| 2015 | 2 | 1 | 3 |
| 2016 | 5 | 1 | 6 |
| 2017 | 1 | 3 | 4 |
| 2018 | 1 | 2 | 3 |
| 2019 | 1 | 3 | 4 |
| 2020 | 5 | 3 | 8 |
| 2021 | 6 | 2 | 8 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tumor Suppressor Proteins" by people in Profiles.
-
Cigarette smoking is a secondary cause of folliculin loss. Thorax. 2023 Apr; 78(4):402-408.
-
E4 engages uPAR and enolase-1 and activates urokinase to exert antifibrotic effects. JCI Insight. 2021 12 22; 6(24).
-
Dependence of ABCB1 transporter expression and function on distinct sphingolipids generated by ceramide synthases-2 and -6 in chemoresistant renal cancer. J Biol Chem. 2022 02; 298(2):101492.
-
Pediatric Gliosarcoma With and Without Neurofibromatosis Type 1: A Whole-exome Comparison of 2 Patients. J Pediatr Hematol Oncol. 2021 11 01; 43(8):e1201-e1204.
-
Long-Term Report of a Comprehensive Molecular and Genomic Analysis in NRG Oncology/RTOG 0424: A Phase II Study of Radiation and Temozolomide in High-Risk Grade II Glioma. JCO Precis Oncol. 2021; 5.
-
"Root"ing for successful T-ALL treatment. Blood. 2021 05 06; 137(18):2422-2423.
-
Increased p53 signaling impairs neural differentiation in HUWE1-promoted intellectual disabilities. Cell Rep Med. 2021 04 20; 2(4):100240.
-
Ceramide synthase 2-C24:1 -ceramide axis limits the metastatic potential of ovarian cancer cells. FASEB J. 2021 02; 35(2):e21287.
-
Targeting sphingosine kinase 1 (SK1) enhances oncogene-induced senescence through ceramide synthase 2 (CerS2)-mediated generation of very-long-chain ceramides. Cell Death Dis. 2021 01 04; 12(1):27.
-
PReferentially expressed antigen in MElanoma (PRAME) expression in BRCA1-associated protein (BAP1)-inactivated melanocytic tumors and deep penetrating nevi: A pilot study. J Cutan Pathol. 2021 Apr; 48(4):597-600.